Michael Makris Invites You to The Research Recap on FEIBA Use in Patients on Emicizumab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, reposted from ISTH on LinkedIn:
”If you treat persons with haemophilia and inhibitors, or if you are affected by the disease, we have a research recap that you may be interested in.
It relates to a paper and commentary published in the RPTH Journal on the use of FEIBA in patients on emicizumab (Hemlibra).
It will be interesting to discuss the issue with Drs Sidonio and Hermans.
Please join us next Tuesday at 11:15 ET, 16:15 UK and 17:15 Europe time.”
Quoting International Society on Thrombosis and Haemostasis( ISTH)‘s post:
”New RPTH Journal Research Recap! Dive into the latest insights from the article:
“Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice.”
Join Robert Sidonio and Cedric Hermans (Lon,Edin) for an engaging discussion led by Michael Makris RPTH Editor-in-Chief.
Discover how emerging evidence is shaping clinical practice.
Don’t miss this expert-driven conversation!
Read ahead:
Register here.
This Research Recap is supported by an educational grant from TAKEDA PHARMACEUTICALS AMERICA, INC.”

Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis